{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:49:18Z","timestamp":1788274158874,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,31]]},"DOI":"10.7759\/cureus.65906","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T06:15:24Z","timestamp":1722492924000},"source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-Induced Ketoacidosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Francisco","family":"Guimar\u00e3es","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Polishchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia","family":"Almeida Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00594-x","article-title":"Pembrolizumab for HER2(+) gastric cancer","volume":"19","author":"Killock D","year":"2022","unstructured":"Killock D. Pembrolizumab for HER2(+) gastric cancer. Nat Rev Clin Oncol. 2022, 19:150. 10.1038\/s41571-021-00594-x","journal-title":"Nat Rev Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0737","article-title":"First-line pembrolizumab\/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811","volume":"17","author":"Chung HC","year":"2021","unstructured":"Chung HC, Bang YJ, S Fuchs C, et al.. First-line pembrolizumab\/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol. 2021, 17:491-501. 10.2217\/fon-2020-0737","journal-title":"Future Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0078-9","article-title":"Pembrolizumab","volume":"3","author":"Khoja L","year":"2015","unstructured":"Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer. 2015, 3:36. 10.1186\/s40425-015-0078-9","journal-title":"J Immunother Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi S","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018, 360:k793. 10.1136\/bmj.k793","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016, 12:2777-89. 10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1085w","article-title":"Autoimmune diabetes associated with pembrolizumab: a review of published case reports","volume":"9","author":"Cheema A","year":"2018","unstructured":"Cheema A, Makadia B, Karwadia T, Bajwa R, Hossain M. Autoimmune diabetes associated with pembrolizumab: a review of published case reports. World J Oncol. 2018, 9:1-4. 10.14740\/wjon1085w","journal-title":"World J Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang LS","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019, 40:17-65. 10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-020-00458-2","article-title":"Fulminant type 1 diabetes: 20\u00a0years of discovery and development","volume":"11","author":"Hanafusa T","year":"2020","unstructured":"Hanafusa T. Fulminant type 1 diabetes: 20\u00a0years of discovery and development. Diabetol Int. 2020, 11:310-4. 10.1007\/s13340-020-00458-2","journal-title":"Diabetol Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/269047-pembrolizumab-induced-ketoacidosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T06:15:26Z","timestamp":1722492926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/269047-pembrolizumab-induced-ketoacidosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.65906","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}